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Sanchez-Lockhart et al. describe a
systems serology platform (Domain
Programmable Arrays) to identify
epitopes targeted after vaccination or
infection. They characterize the humoral
response in rVSV-DG-EBOV-
glycoprotein-vaccinated non-human
primates, observing bias on the
immunoglobulin isotype epitope
recognition pattern, showing the value of
the tool to qualitatively measure humoral
responses.
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Development of an effective vaccine became a
worldwide priority after the devastating 2013–2016
Ebola disease outbreak. To qualitatively profile the
humoral response against advanced filovirus vac-
cine candidates, we developed Domain Programma-
ble Arrays (DPA), a systems serology platform to
identify epitopes targeted after vaccination or filovi-
rus infection. We optimized the assay using a panel
of well-characterized monoclonal antibodies. After
optimization, we utilized the system to longitudinally
characterize the immunoglobulin (Ig) isotype-spe-
cific responses in non-human primates vaccinated
with rVSV-DG-EBOV-glycoprotein (GP). Strikingly,
we observed that, although the IgM response was
directed against epitopes over the whole GP, the
IgG and IgA responses were almost exclusively
directed against the mucin-like domain (MLD) of the
glycan cap. Further research will be needed to char-
acterize this possible biased IgG and IgA response
toward the MLD, but the results corroborate that
DPA is a valuable tool to qualitatively measure the
humoral response after vaccination.
INTRODUCTION
Filoviruses are single-stranded negative-sense RNA viruses that
can cause severe hemorrhagic fever in primates with high fatality
rates (Kuhn, 2008). Ebola virus disease (EVD) has an incubation
periodof up to21days in humans, duringwhichadefective innate
immune response usually leads to unbalanced inflammation and
immune response dysregulation and, ultimately, the collapse of
adaptive immunity (Messaoudi et al., 2015; Prescott et al.,
2017). In fatal cases, T and B lymphocytes undergo significant
apoptosis, whereas specific humoral responses are barely
detectable (Agrati et al., 2016; Baize et al., 1999). In contrast, re-
covery has been associated with viral clearance preceded by the
development of robust T cell responses and long-lasting Ebola
virus (EBOV)-specific serum immunoglobulins (McElroy et al.,
2015; Ruibal et al., 2016). Moreover, in non-human primates
(NHPs), cocktails of anti EBOV glycoprotein (GP) monoclonal
antibodies were shown to protect from infection (Olinger et al.,
2012; Qiu et al., 2014), a strong humoral response was linked to
vaccine efficacy (Marzi et al., 2013; Mire et al., 2015), and conva-
lescent serum from vaccinated NHPs that survived either EBOV
or Marburg virus (MARV) challenge provided protection by pas-
sive transfer (Dye et al., 2012). Therefore, it is generally accepted
that a strong humoral response against EBOV proteins plays an
important role in survival and prophylactic protection. However,
protection has also been achieved through the cellular compo-
nent of the acquired immune response (Sullivan et al., 2011),
indicating that immunity is most likely mediated by a balanced
combination of both humoral and cellular immune responses.
AlthoughRussia andChina approved EBOV vaccines, there are
no current Food and Drug Administration (FDA)-approved
vaccines for prevention of EBOV infection. The development of
an effective and long-lasting vaccine has becomeaworldwide pri-
ority after the devastating 2013–2016 EVD outbreak that mainly




vaccine platforms are being developed where the EBOV
GP is the main immunogen utilized (Reynolds and Marzi,
2017). The most advanced EBOV vaccine candidates under
development through the FDA process are the live replicating
recombinant vesicular stomatitis virus-DG-EBOV GP (rVSV-
EBOV), the recombinant adenovirus serotype 26 EBOV-GP
(Ad26-EBOV) combined with a modified vaccinia Ankara-
EBOV-GP (MVA-EBOV), and the replication-deficient chim-
panzee adenovirus type 3-EBOV GP (ChAd3-EBOV) (Pavot,
2016). These vaccines were shown to induce high levels of
EBOV GP-specific antibodies and to be safe and well toler-
ated in clinical trials conducted in the United States, Europe,
and Africa (Chen et al., 2017; Henao-Restrepo et al., 2015,
2017; Kennedy et al., 2017; Regules et al., 2017; Stanley
et al., 2014).
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The EBOV genome is about 19 kb long and encodes seven
structural proteins: a nucleoprotein (NP), four viral proteins
(VP40, VP35, VP30, and VP24), a GP, and an RNA-dependent
RNA polymerase (L) as well as two non-structural proteins, solu-
ble GP (sGP) and small soluble GP (ssGP) (Kuhn, 2008; Mehedi
et al., 2011). Transcriptional editing of the GP gene results in
the expression of a 676-amino acid-long transmembrane pro-
tein. GP is post-translationally cleaved by the cellular furin prote-
ase, which generates GP1 and GP2. GP1 is involved in host cell
attachment, whereas GP2 is involved in membrane fusion.
Both GPs form a disulfide-linked heterodimer that trimerizes at
the cell surface of the virion before budding (Beniac and Booth,
2017). Traditionally, three domains are identified in GP1: base
and head (where the receptor binding domain resides) and
glycan cap (Lee and Saphire, 2009; Wang et al., 2016). The
150-amino acid C-terminal portion of the glycan cap contains
the mucin-like domain (MLD), which is highly N- and O-glycosy-
lated and has very low secondary structural complexity. Within
GP2, four main domains are described: fusion loop (FL), N- and
C-terminal heptad repeat (NHR and CHR), membrane-proximal
external region (MPER), and the transmembrane (Lee et al.,
2017).
Several methods had been utilized to dissect the targets of the
humoral response during filovirus natural infection. ELISA was
used on Sudan virus (SUDV) survivors to show that the main
targets were NP followed by VP30, GP, and VP40 (Sobarzo
et al., 2013). Western blot on EBOV survivors identified NP and
VP40 as the preferential targets and, to a lesser degree, VP35
and GP (Leroy et al., 2000). Finally, linear peptides (15-mers)
identified immunodominant sites in VP35, VP40, NP, and GP
on asymptomatic individuals, but only in the GP from Gabon
EBOV survivors (Becquart et al., 2014). Unfortunately, limited
comparable information is available from post-vaccination
studies. Until now, the main focus has been the determination
of immunoglobulin G (IgG) titers by ELISA or neutralization
assays, which provides no information regarding the immunodo-
minant regions targeted by the humoral response.
There is a vast body of work with monoclonal antibodies
(mAbs), identifying and characterizing regions on the EBOV GP
associated with neutralization and/or protection (Bale et al.,
2012; Dias et al., 2011; Holtsberg et al., 2015; Murin et al.,
2014). Protective mAbs have been described against epitopes
located in non-conserved regions such as the MLD (mAb 6D8
or 13F6; Wilson et al., 2000a) as well as located in highly
conserved areas like the GP FL (mAb ADI-15878 or ADI-15742;
Wec et al., 2017). Whether both types of regions are equally
efficient in providing protection is not known yet, but immunodo-
minant epitopes might not be adequate vaccine targets to con-
trol viral infection. This scenario has been observed in other viral
infections. For influenza virus, analysis of the hemagglutinin (HA)
antigenic structure has shown that the highly variable globular
HA1 subunit is the main immunodominant antigenic target
reducing the efficacy of vaccination (Neu et al., 2016). To the
contrary, conserved regions located in the HA2 subunit elicit
broad-spectrum neutralizing antibodies but less frequent hu-
moral responses. Similarly, for HIV, broad-spectrum antibodies
capable of neutralizing most circulating strains were mapped
to areas of the envelope protected by a glycan cap shield,
whereas most of the response is directed to highly variable im-
munodominant loops (Mascola and Montefiori, 2010; McCoy
and Weiss, 2013; Stamatatos et al., 2009; Zhou et al., 2013).
However, a qualitative assessment, at the epitope level, of a
polyclonal response is missing in filovirus vaccination or
infection.
To define the linear epitopes eliciting a measurable response
against filoviruses and gather information about their immuno-
dominance during either viral infection or vaccination, we devel-
oped Domain Programmable Arrays (DPA), a phage display,
high-throughput serological platform for epitope mapping.
DPA takes advantage of a classical phage display system,
methods of high-throughput oligonucleotide synthetic to design
the detection array, and a bioinformatics approach to compre-
hensively identify domain variants within epitopes. The platform
was initially optimized with a panel of well-defined mAbs, alone
or in mixtures. After optimization of the assay, we used DPA to
qualitatively asses a polyclonal immune response from NHPs
vaccinated with rVSV-EBOV. We longitudinally characterized
the regions and epitopes on EBOV GP recognized by the
different immunoglobulin isotypes present in the serum. The
amino acid C-terminal portion of the glycan cap, the MLD of
EBOV GP, proved to be the most immunodominant region con-
taining several linear epitopes. Intriguingly, the pattern of
epitope recognition was distinct among different immunoglob-
ulin isotypes. Although the IgM response was widespread
over the whole EBOV GP, IgG and IgA showed a focused
response toward epitopes at the MLD of the protein. The results
presented showed that DPA is a useful tool to qualitatively
measure a polyclonal response during vaccination and resulted
in the intriguing preliminary observation that IgG and IgA re-
sponses to EBOV GP in NHPs vaccinated with rVSV-EBOV
were directed toward a highly diverse area that can accommo-
date mutations but diverted from areas that cannot easily
change.
RESULTS
Design of the DPA
Protein-coding domain sequences from every strain of filovirus
(EBOV, SUDV, Taı̈ Forest virus [TAFV], Bundibugyo virus
[BDBV], Reston virus [RESTV], MARV, Ravn virus [RAVN], and
Lloviu virus [LLOV]) deposited into GenBank as of December
2016 were retrieved, and alignments were created for sGP and
the seven structural filovirus genes. Oligonucleotides encoding
either 30- or 36-amino acid (aa)-long peptides and tiled every
7 aa (Figure 1A) were designed over the coding alignment of all
open reading frames (ORFs). Oligonucleotides coding identical
sequences were eliminated from the array design. The remaining
oligonucleotides (13,573 oligonucleotides for the 36-aa array
and 12,735 for the 30-aa array) encoding unique codon-opti-
mized peptides were synthesized on high-density DNA microar-
rays and cloned into a T7 phage display system. The resulting
libraries (Filo30 or Filo36 for 30- or 36-aa displayed peptides,
respectively) were deep-sequenced to confirm that more than
85% of the intended peptides were successfully displayed.
Libraries were stored in 10% glycerol at 20C until they were
used for experimentation.
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IgM, IgG, or IgA antibodies were separately captured in the
solid phase (Figure 1B), and the phage library was added for
panning. After multiple washes, the bound fraction was recov-
ered for subsequent composition analysis. Only one round of
panning was performed to avoid bias during phage re-amplifica-
tion (Derda et al., 2011). The original phage library and the bound
subset were sequenced and analyzed to detect differentially
expressed clusters of enriched oligonucleotides (Figure 1C).
Given the repetitive and tiled nature of the array design, these
enriched clusters are composed of several peptides that overlap
over the region of specific recognition. The common region
among all recognized peptides within the enriched cluster de-
fines the minimal epitope.
DPA Performance Using mAbs against Filovirus GPs
mAbs of known specificity against filoviruseswere utilized to vali-
date the platform. mAbs 6D8, 13F6, 14G7, and 12B5 recognize
epitopes on EBOV GP, 3C10 and 17F6 on SUDV GP, and 3F2
and 7E6 on MARV GP. All mAbs were developed at the United
States Army Medical Research Institute of Infectious Diseases
Figure 1. Schematic Representation of the
DPA Assay
(A) Oligonucleotide array design for the filovirus
library. Either 108-nt-long (36 aa) or 90-nt-long
(30 aa) libraries were generated, both with a 21-nt
(7 aa) tiling to the subsequent oligonucleotide.
(B) The phage enrichment (panning) assay consists
of a specific Ig isotype capture, one round of
panning with the phage library, and retention of the
bound fraction for further analysis.
(C) Regions of oligonucleotide enrichment after
panning generate clusters (simulated data repre-
sentation), and within those clusters, the over-
lapping area will define the minimum epitope (red
labeling). All viral variants are covered by the
oligonucleotide design (underlined aa).
(USAMRIID) and have been described
previously (Lee et al., 2008; Olal et al.,
2012; Wilson et al., 2000a). Filo30 and
Filo36 phage libraries performed equiva-
lently, both enriching for comparable
oligonucleotide clusters and identifying
equivalent minimal epitopes that matched
the described epitope for each mAb
(Table S1A). As a representative example,
results for mAb 6D8 are shown (Figure 2).
Only one cluster was enriched between
position 364–427 using Filo36 and 371–
421 for Filo30 (Figures 2A, S1A, and S2A).
The minimal epitope identified for mAb
6D8 was VYKLD(I/T)SE using Filo36 or
VYKLD(I/T)SE(A/T) using Filo30. Both re-
sults perfectly match the described
epitope for thismAb (VYKLDISEA) (Wilson
et al., 2000a). Moreover, the results also
illustrate the richness of the approach,
which is a consequence of the coverage
of the whole filovirus diversity on the phage library. mAb 6D8
binds to VYKLDISE, which is found in most viral strains from the
1995 EVD outbreak in Kikwit (Democratic Republic of the Congo,
formerly Zaire)—for example, EBOV/H. sapiens-tc/COD/1995/
Kikwit-9510622 (GenBank: ALT19754)—but also to VYKLDTSE,
which is found in viral strains from the 2013 EVD outbreak, like
EBOV/H. sapiens-wt/SLE/2014/Makona-20141582 (GenBank:
AKG95596). The result of the analysis of mAb 14G7 showcases
additional advantages of the platform. Both libraries, Filo30 and
Filo36, enriched a cluster in region 455–518 and 462–512, respec-
tively (Figures 2B, S1B, and S2C), identifying theminimal epitope
NT(I/T)AGVAG (Filo36) or NT(I/T)AGVAGL (Filo30), in agreement
with the described epitope formAb 14G7 (Olal et al., 2012). How-
ever, 14G7 also enriched for the RESTV peptide NTVSEVAG,
suggesting that NTXXXVAG is the minimum binding sequence
necessary for mAb 14G7.
Finally, to demonstrate that its utility was not restricted to indi-
vidual mAbs, different mixtures of mAbs were tested. Epitopes
were successfully identified in all cases. A representative exper-
iment, utilizing a cocktail containing mAbs 6D8 (EBOVGP), 3C10
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(SUDV GP), 14G7 (EBOV GP), and 7E6 (MARV GP) is shown in
Figure S2.
Polyclonal Response Evaluation in Vaccinated NHPs
DPA was utilized to identify the epitopes targeted by 3 NHPs
(Macaca fascicularis) vaccinated intramuscularly (IM) with 1 3
107 PFUs (plaque-forming units) of rVSV-EBOV. Blood samples
were collected 7 days pre-vaccination and 14, 21, 28, and
42 days after vaccination. IgM, IgA, and IgG were separately
captured using specific mAbs and assayed using the Filo30
library. Consistent with a robust polyclonal response, clusters
of enrichment were observed along the ORF of EBOV GP. How-
ever, the enrichment pattern recognized by each immunoglob-
ulin (Ig) isotype was strikingly distinct (Figure 3A). Several
clusters of enrichment distributed along the GP1 (base, head,
and glycan cap) andGP2 (folding loop, HRs, andMPER) subunits
were readily observed by day 14 when panning with enriched
IgM. This pattern was maintained at later time points, although
a focus of the response on the glycan cap can be observed as
the immune response progresses. IgM responses were detected
during the entire duration of the experiment, and targeted
epitopes remained broad even after an IgG response become
apparent. To the contrary, when analyzing the IgA and IgG
responses that were detected at the first time point of collection
after vaccination (day 14), they were almost exclusively focused
on the glycan cap of the GP, especially at the MLD, and main-
tained on days 21, 28, and 42.
To evaluate the effect of different vaccine dosages, three
groups of animals were vaccinated intramuscularly with rVSV-
EBOV using a dose of 1 3 108 PFUs (n = 4), 2 3 107 PFUs
(n = 4), and 3 3 106 PFUs (n = 4). Based on the results from
the previous experiment, samples were collected on days 0, 7,
Figure 2. Oligonucleotide Cluster Enriched
by the mAb 6D8 and 14G7 Using the Filo36
or Filo30 Phage Library
(A) The mAb 6D8 enriched for an oligonucleotide
cluster at the MLD of the EBOV GP. This cluster is
composed of 68 different oligonucleotides dis-
playing EBOV peptides, spanning from aa 364 to
427, and contains a minimal overlapping region of
VYKLD(I/T)SE using Filo36. An equivalent minimum
epitope, VYKLD(I/T)SE(A/T), was obtained using
Filo30. Thus, the cluster is composed of 52 oligo-
nucleotides and spans from aa 371 to 411.
(B) The mAb 14G7 enriched for a cluster at position
455 to 519, containing the 20 oligonucleotides and
the minimal overlapping sequence of NTIAGVAG
using the Filo36 phage library. This mAb also
enriches for a RESTV peptide, containing, in that
region, the aa sequence NTVSEVAG (Figure S1).
Using Filo30, the cluster expands from aa 462 to
512, containing 14 oligonucleotides, and with an
overlapping region of NTIAGVAGL.
See also Figures S1 and S2 and Table S1.
and 28 post-vaccination, which thus
included an earlier time point (day 7)
compared with the previous experiment.
Animals vaccinated with the two higher
doses (1 3 108 and 2 3 107) confirmed the pattern observed
previously (Figure 4). IgM responses targeted epitopes in the
GP1 and GP2 regions, whereas IgG responses were almost
exclusively focused on the MLD. IgG responses were readily de-
tected on day 7 against some epitopes and greatly expanded by
day 28 in most of the animals, whereas IgM responses were
broad, detected by day 7, and maintained through day 28.
Animals vaccinated with the lower dose (3 3 106) showed a
slightly different pattern (Figure 4). IgM responses still remained
broader than IgG responses, but almost no epitope was recog-
nized at the base or head region of the EBOV GP1. Targeted
epitopes were restricted to the glycan cap (including the MLD)
and GP2 regions. IgG responses were restricted to the MLD;
however, on day 28, they were mainly targeting epitopes be-
tween amino acids 392–480, in contrast with the broader targets
observed at higher doses (region 300–500). These animals were
challenged on day 28; all animals were protected and survived
the EBOV challenge (data not shown).
Epitope Mapping of the Polyclonal Response
To further expand on these results, analysis of the minimum epi-
topes within the enriched cluster was done. Although it was
straightforward to logically infer the minimal epitope on clusters
formed by a discrete number of oligonucleotides (approximately
10–15 oligonucleotides) that expanded around 40–50 AA posi-
tions (Figure S3A), the identification was more challenging
when broader clusters, likely containing more than one targeted
epitope, were analyzed (Figure S3B). Thus, on these complex
regions, several non-overlapping aa regions were evaluated by
western blot (Figure S4).
Confirming the DPA observations, epitopes at the MLD were
equally recognized by the three isotypes tested (IgM, IgG, and
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IgA) on most animals, whereas epitopes in other regions were
mainly isotype-specific (Figure 3B). Epitopes at the base or
head region of GP1 were almost exclusively recognized by the
IgM isotype and, exceptionally, by IgA. The only epitope consis-
tently recognized by IgM in the base or head region was E(N/D)
CYN(L/F)EIKKPDGSEC. Similarly, almost no IgG-recognizable
epitopes were identified within the N terminus of the glycan
cap region, whereas similar IgA- and IgM-recognizable epitopes
were detectable. Epitopes at the FL or near the C-terminal end of
GP2 were almost exclusively recognized by IgM. These results
suggest that theMLD is immunodominant and promotes Ig class
switching, whereas epitopes outside of that area are T-indepen-
dent, resulting in antibodies reacting against them, not progress-
ing toward class switching.
DISCUSSION
A Platform for Dissecting the Humoral Immune
Response
Phage display technology has been widely utilized for screening
and identification of protein-protein interactions (Mullen et al.,
2006; Pande et al., 2010). Because of its ability to link the geno-
type and phenotype, this technology is commonly used for
epitope or paratope discovery and antibody engineering
(Kretzschmar and von R€uden, 2002; Wang and Yu, 2004).
Regardless of its potential, areas needing improvement have
been identified: develop strategies for construction and produc-
tion of better phage libraries (Fack et al., 1997) and avoid phage
growth bias during the sequential panning enrichment (Derda
et al., 2011; ’t Hoen et al., 2012). Our assay explicitly addresses
each of these problems. First, a bioinformatics approach was
used to identify all potential domain variants of the target
pathogen to cover virus variability. This improvement allows
generation of a broad and diverse oligonucleotide array that cir-
cumvents the use of the random fragmentation of a single viral
strain. Second, methods of high-throughput, high-fidelity DNA
synthesis were utilized to generate a true programmable real-
time serological array. Third, any multi-sequence amino acid
FASTA sequence file could be used as input in the domain array
design pipeline to enable incorporation into the array of any novel
pathogen strain immediately after its sequence becomes avail-
able. This last advantage was used to quickly incorporate
Figure 3. Regions of Antigenic Recognition on EBOV GP in Vaccinated NHPs
Three NHPs (Macaca fascicularis), 2 male and 1 female, were vaccinated IM as described in the STAR Methods.
(A) Areas of oligonucleotide enrichment are represented with bars under the linear map of EBOV GP. Blue bars represent the entire ORF from the EBOV GP, Red
represents the head/base area, green the glycan cap, and light green (inside green) the MLD region. The figure shows the isotype pattern of region recognition,
IgM (top, black), IgA (middle, green), and IgG (bottom, purple), on days7, 14, 21, 28, and 42 for the three animals vaccinated with 13 107 PFUs of rVSV-EBOLA.
(B) Representation of the most immunodominant and frequent epitopes by NHP and Ig isotype. Minimum amino acid sequences (epitopes) identified by DPA are
illustrated. Black represents epitopes recognized by IgM, green by IgA, and purple by IgG. DPA was run in three technical triplicates.
See also Figures S3 and S4.
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sequence variants from the 2013 EVD outbreak into the array,
allowing immediate evaluation of serum from the outbreak in
our platform (data not shown). Finally, the protocol of phage
enrichment was developed to include only one panning round,
which eliminates bias during phage growth.
The diversity within the phage library and programmable
feature of DPA provides a key advantage compared with
classical phage display protocols. Each gene alignment of every
filovirus sequence available for a given genus was parsed to
create unique 30- or 36-mer AA sequences using a 7-aa step
tiling strategy (Figure 1). This overlapping design creates redun-
dancy in the system, which is crucial to define the minimal bind-
ing site (putative epitope). The improvement allows DPA to not
only map the region of antibody recognition, as other phage
technologies do, but also delineates the humoral response at
the epitope level (Figure 3). The inclusion of all natural occurring
diversities allows assessment of sequence variation within the
epitope, identifying cross-reactivity of the response to other viral
strains (e.g., several of the epitopes identified during NHPs
vaccination recognized hybrid clusters, also comprising oligonu-
cleotides encoding SUDV, BDBV, RESTV, and/or TAFV GP
peptides). Additionally, it allows assessment of the breadth of
the humoral responsewithin the diversity displayed; for example,
at the 6D8 mAb minimal binding site, the substitution of the
isoleucine (I) at position 397 for a threonine (T) in the VYKLDISE
epitope is tolerated. Thus, the effect of antigenic drift can be
easily tested on individual mAbs, cocktails, or polyclonal sera.
This is fundamentally different from previous applications using
random DNA fragmentation (Khurana et al., 2009, 2011, 2016),
which cannot cover the full diversity space, be used to define
minimum epitopes, or provide information about crucial binding
residues inside the defined epitope. Finally, DPA evaluates
the targets of all ORFs of the virus family in one assay. For exper-
imental vaccines that are multivalent (different filoviruses) or
multicomponent (different proteins from the same virus), the
assay can simultaneously identify the immunodominant epi-
topes for all targets, reducing the amount of samples needed
and the time to gather the information.
The assay process is automatable, reproducible, and statisti-
cally robust. Phage libraries are fully characterized and grown at
high titers, allowing stability of this reagent for a long period of
time. Deep high throughput sequencing (HTS) of the library
allows determination of the coverage and ensures that minimal
errors are introduced during oligonucleotide synthesis, cloning,
and expansion of the phage library. The process of panning
has been further refined to resemble classical ELISA protocols.
No multiple rounds of panning are performed, eliminating errors
because of phage amplification bias during growth. The report-
ing system of the assay is done by next-generation sequencing
(NGS), allowing analysis of a high number of samples with high
reproducibility. Moreover, each sample is assayed and analyzed
in triplicate, allowing robust statistical analysis to determine
enrichment. DPA is agnostic and can be expanded to dissect
the humoral response against other viral families or to survey
Figure 4. EBOV GP Epitope Immunodominance in Vaccinated NHPs
Four NHPs (Macaca fascicularis) per group, 2 male and 2 female, were vaccinated IM as described in the STAR Methods. Shown are regions of antigenic
recognition on EBOVGP in NHPs vaccinated with 13 108, 23 107, or 33 106 PFUs of rVSV-EBOLA. Areas of oligonucleotide enrichment under the linear map of
EBOVGP are shown from the four NHPswithin each dose group. Equivalent to Figure 3, blue bars represent the ORF of GP, red bars represent the base and head
area, green the glycan cap, and light green the MLD. Black bars represent epitopes recognized by IgM and purple bars those recognized by IgG. DPA was run in
three technical triplicates.
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seroprevalence against multiple viruses in a given geographical
location.
One of the general limitations of the phage display technology
is the fact that it is displaying peptides in the context of a phage
protein (for T7, the capsid) and, consequently, cannot recreate
the folding and complex structure of native viral proteins. On
top of that, glycosylation patterns will also differ and affect anti-
body recognition. It has been posited that by displaying longer
peptides or protein domains obtained by random DNA fragmen-
tation, phage display systems might retain the ability to display
conformational structures. However, proper folding of complex
proteins like EBOV GP is unlikely to occur in the context of the
phage protein external domain and will certainly fail to display
tertiary or quaternary structures and, ultimately, provide no sub-
stantial advantages over the use of smaller peptides (Khurana
et al., 2016; Wang and Yu, 2004). Even when the DPA assay
will mainly be assessing the humoral response against linear
epitopes, it is still valuable to longitudinally follow the humoral
immune response induced by a virus infection or vaccination,
monitor the expansion and maturation of B clones responding
to those limited set of epitopes, and evaluate isotype switching
over time.
Dissecting the Humoral Immune Response against a
Candidate EBOV Vaccine
rVSV-EBOV has been shown to provide protection in several
animal models, including mice and NHPs (Marzi et al., 2013,
2015; Mire et al., 2016). When administered to humans, rVSV-
EBOV has promoted robust antibodies titers with measurable
in vitro neutralization properties and T cell activation (Farooq
et al., 2016; Regules et al., 2017). In our second experiment,
animals vaccinated with 3 3 106, 2 3 107, and 1 3 108 PFUs
were challenged IM with 1,000 PFUs of a Kikwit variant of
EBOV (USAMRIID stock R4415) on day 42 after vaccination,
and those animals were protected. In addition, a ring vaccina-
tion cluster-randomized trial performed in Guinea showed that
rVSV-DG-EBOV GP might be useful to reduce transmission in
contact cases (Kucharski et al., 2016). All of these results indi-
cate that the vaccine elicits protective short-term immunity.
However, the different pattern of the IgM and IgG epitope
recognition detected using DPA suggests that Ig class switch-
ing might be partially impaired, which could have an effect on
long-term protection and memory generation. It is premature
at this point to conclude that this observation raises concern
about this particular vaccine. Given the lack of comparative
data to evaluate the response after infection or against other
vaccine platforms, we cannot conclude whether this phenome-
non is vaccine-specific or a result of the EBOV GP nature as an
antigen. The VSV-G at the virion surface has been shown to
exist in a highly repetitive structure, with a two-dimensional
spacing of 5–10 nm (Dintzis et al., 1976), whereas the same pro-
tein expressed at the infected cell surface is highly mobile and
poorly organized (Johnson et al., 1981). The virion organization
promotes early generation of IgM antibodies, providing rapid
short-term protection (Bachmann and Zinkernagel, 1997). Our
results and others (Schmidt et al., 2013) demonstrate that IgM
responses are dominant over the IgG responses even on day
28. However, we can only speculate that the organization of
the EBOV GP at the virion surface in the rVSV-EBOV vaccine
might favor the induction of a T-independent response. Unfortu-
nately, without comparison with the humoral response to an
alternative EBOV vaccine or from EVD human survivors, we
cannot corroborate this hypothesis. Further experimentation in
this area is warranted.
NHPs vaccinated with rVSV-EBOV showed a class-switched
(IgG and IgA) humoral response focused largely on the MLD of
the glycan cap of EBOV GP. Although this region contains
epitopes that, when targeted by antibodies, can promote
neutralization and protection to viral infection, those epitopes
can also mutate, producing viral escape mutants (Kugelman
et al., 2015). Results from the Viral Hemorrhagic Fever Immuno-
therapeutic Consortium (VIC) project, which analyzed the
neutralizing properties of hundreds of EBOV mAbs, established
that antibodies directed against the base and the FL are the
ones associated with better protection (Bale et al., 2012; Born-
holdt et al., 2016; Dias et al., 2011; Flyak et al., 2016; Holtsberg
et al., 2015; Keck et al., 2015; Murin et al., 2014; Wec et al.,
2017). In that context, the distinct pattern of recognition of
each Ig class should be studied further study because IgG
responses detected by DPA became almost completely focused
on the MLD region, with minimal recognition of other regions
(Figures 3 and 4).
Although the differential immunodominance between Ig
classes was not reported elsewhere, a previous report using
overlapping 15-mers also identified the immunodominance of
epitopes within the MLD (Becquart et al., 2014). We did consider
the possibility that the lack of secondary complexity of the MLD
might explain the dominance in our analysis, given our restriction
in the detection of conformational epitopes. However, this expla-
nation alone would not be enough to account for all of the data
because we continue to detect an IgM response that broadly
recognizes all regions of EBOV GP, at least until day 42 after
vaccination (Figure 3). This confirms that lineal epitopes present
in these regions can generate a response but that isotype-
switched Igs reacting against these epitopes are not generated
or that they are quickly lost.
There is much evidence that viral pathogens evolved to divert
the immune response away from key areas of viral proteins that
cannot tolerate change, directing it toward areas that can handle
more variation without a significant fitness cost. Identification of
those regions is the basis for the development of broad neutral-
ization antibody therapies or universal influenza vaccine strate-
gies. This type of strategy has successfully been applied to
influenza (Shcherbinin et al., 2016) and HIV (Kwong et al., 2013).
The results obtained with our platform demonstrate the
power of system serology approaches to dissect the immune
response during vaccination. Our analysis of the epitopes tar-
geted highlights the fact that titers of Ig in serum are not only
insufficient to establish accurate correlates of protection, but
they are also misleading regarding the quality of the response.
Novel tools like immune receptor (B cell receptor [BCR] and
T cell receptor [TCR]) repertoire characterization (Georgiou
et al., 2014; Reddy and Georgiou, 2011) and systems serology
(Ackerman et al., 2017) are becoming the new standard. We
propose to add high-throughput epitope mapping via DPA to
that arsenal.
1056 Cell Reports 24, 1050–1059, July 24, 2018
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B rVSV-DG-EBOV-GP vaccination study design
d METHOD DETAILS
B Monoclonal antibodies
B Generation of the filovirus phage library
B Immunoglobulin isotype capture and panning
B Phage library and bound fraction sequencing
B Western-blot analysis
B Bioinformatic analysis pipeline
B Reporting
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Statistical analysis
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at https://doi.org/10.1016/j.celrep.2018.06.077.
ACKNOWLEDGMENTS
Opinions, interpretations, conclusions, and recommendations are those of the
author and are not necessarily endorsed by the United States Army. Research
was conducted under an IACUC-approved protocol in compliancewith the An-
imalWelfareAct, PHSPolicy, andother federal statutes and regulations relating
to animals and experiments involving animals. The facility where this research
was conducted is accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care, International and adheres to principles stated
in the Guide for the Care and Use of Laboratory Animals, National Research
Council, 2011. Funding for this research was provided by the Defense Threat
Reduction Agency (CB10138) under USAMRIID project number 31741630.
AUTHOR CONTRIBUTIONS
Conceptualization, M.S.-L., J.C.T., J.R.K., M.L.P., and G.F.P.; Methodology,
M.S.-L., J.R.K., and G.F.P.; Software, J.R.K., K.Y.G., E.C.V., and B.P.P.; Vali-
dation, M.S.-L., J.R.K., and G.F.P.; Formal Analysis, J.R.K., E.C.V., and
K.Y.G.; Investigation, M.S.-L., D.S.R., J.C.G., and J.C.T.; Resources,
M.S.-L., J.R.K., J.C.T., M.L.P., and G.F.P.; Data Curation, J.R.K., K.Y.G.,
E.C.V., and B.P.P.; Writing – Original Draft, M.S.-L. and G.F.P.; Writing –
Review & Editing, M.S.-L., J.R.K., M.L.P., and G.F.P.; Visualization, M.S.-L.
and G.F.P.; Supervision, M.S.-L., M.L.P., and G.F.P.; Project Administration,
M.S.-L. and G.F.P.; Funding Acquisition, M.L.P. and G.F.P.
DECLARATION OF INTERESTS
The authors declare not competing interests.
Received: February 12, 2018
Revised: April 20, 2018
Accepted: June 18, 2018
Published: July 24, 2018
REFERENCES
Ackerman, M.E., Barouch, D.H., and Alter, G. (2017). Systems serology for
evaluation of HIV vaccine trials. Immunol. Rev. 275, 262–270.
Agrati, C., Castilletti, C., Casetti, R., Sacchi, A., Falasca, L., Turchi, F., Tumino,
N., Bordoni, V., Cimini, E., Viola, D., et al. (2016). Longitudinal characterization
of dysfunctional T cell-activation during human acute Ebola infection. Cell
Death Dis. 7, e2164.
Bachmann, M.F., and Zinkernagel, R.M. (1997). Neutralizing antiviral B cell
responses. Annu. Rev. Immunol. 15, 235–270.
Baize, S., Leroy, E.M., Georges-Courbot, M.C., Capron, M., Lansoud-Sou-
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Goat Anti-Monkey IgM m Polyclonal Antibody KPL 071-11-031
Goat Anti-Monkey IgG g Polyclonal Antibody KPL 071-11-021
Goat Anti-Monkey IgA a Polyclonal Antibody KPL 071-11-011
Anti-Goat HRP Antibody Protein simple 043-522-2
Bacterial and Virus Strains
BL21 glycerol stock EMD Millipore 69386-0.2ML
Critical Commercial Assays
T7Select 415-1 cloning kit EMD Millipore 70015-3
T7Select415-1 EcoRI/Hind III Vector Arms EMD Millipore 70017-5UG
T7Select packaging extracts EMD Millipore 69139-25UL
T7SelectUP primer EMD Millipore 70005-500PM
T7SelectDOWN primer EMD Millipore 70006-500PM
T7Select Packaging Kit EMD Millipore 70014
150x15mm plates Fisher Scientific FB0875714
100x15mm plates Fisher Scientific FB0878712
Phusion Hot Start Flex DNA Polymerase New England Biolabs M0535L
EcoRI HF New England Biolabs R3101L
Hind III HF New England Biolabs R3104L
DNA Clean & Concentrator-5 Zymo Research D4014
Zymoclean Gel DNA Recovery Kit Zymo Research D4008
T4 DNA Ligase New England Biolabs M0202L
96 well bottom immune-plate for ELISA Thermo Scientific 442404
Adhesive Film for microplates VWR 60941-120
WES 12-230 kDa master kit Proteins Simple PS-MK02
PrepX Complete ILMN DNA Library Kit Wafergen 400075
KAPA Library Amplification Kit Kapa Biosystems KK2621
MiSeq Reagent Kit v3 (600 cycle) Illumina MS-102-3003
Streptavidin HRP- Conjugate Protein simple 042-414
12-230 kDa WES separation module 8x25 capillary Protein simple SM-W004
WES Reagents (Biotinylated ladder, standard,




DPA data SubmissionID: SUB4104551 https://www.ncbi.nlm.nih.gov/
bioproject/475600BioProject ID: PRJNA475600
Experimental Models: Organisms/Strains
Non-human primates (Macaca fascicularis) USAMRIID animal colony N/A
Oligonucleotides
GGA GCT GTC GTA TTC CAG TC EMD Millipore T7 forward primer
CCC CTC AAG ACC CGT TTA GAG GCC C EMD Millipore T7 reverse primer
GTCTCCGACTCAG Eurofins Primer 1
ATCACCGACTGCC Eurofins Primer 2
Software and Algorithms
DPA analysis pipeline Github.com https://github.com/kygarcia/
DPA_Analysis_Pipeline
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Dr. Gustavo Palacios (Gustavo.f.palacios.ctr@mial.mil).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
rVSV-DG-EBOV-GP vaccination study design
Research was conducted under an IACUC approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other
Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conduct-
ed is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to
principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.
The rVSV-DG-EBOV-GP, containing the VSV genome with the ebolavirus (isolate Kikwit) glycoprotein (GP) in place of the
VSV-glycoprotein (G), was used in the vaccination.
The objective of the first study was to investigate the immunity generated by the vaccine. On day 0, three NHPs (Cynomolgus
macaques - Macaca fascicularis) were vaccinated with 1x107 PFU of rVSVEBOV inoculum injected into the thigh muscle (intramus-
cularly - IM). Cynomolgus macaques were of Asian origin, mixed male and female (two females and one male), at least 4 years old
(6 to 8), and obtained from the USAMRIID colony Animal. Whole blood was collected on day 0, 14, 21, 28 and 42. These animals were
not challenged with EBOV.
In the second study, NHPs were vaccinated IM with either 1x108, 2x107 or 3x106 PFU. Four animals (two males and two females)
were assigned to each group. Animals ranges from 5 to 8 years old. On day 35, animals were exposed (IM) to a target dose of
1,000 PFU of the Kikwit variant EBOV seed stock. This EBOV variant was obtained from a 65-year old female during an outbreak
occurring in 1995 in the Democratic Republic of the Congo (formerly Zaire). All the animals survived the challenge. Whole blood
was collected at day 7, 7 and 14.
All the animals in the two described experiments were randomized using the factors of sex, weight, and age, and blinded until the
end of the study. Whole blood was collected using a 2mL Z SerumClot Activator Greiner Vacuette tube. The tube was gently inverted
by hand, allowed to clot and subsequently centrifuged (Thermo Scientific) at 3,000 x g for 10 minutes at ambient temperature. Serum
was separated from the clot within 2 hours of collection and stored at 20C for further analysis.
METHOD DETAILS
Monoclonal antibodies
EBOVGP specificmonoclonal antibodies 6D8, 13F6, 14G7 and 12B5; SUDVGP specificmonoclonal antibodies 3C10 and 17F6; and
MARV GP specific monoclonal antibodies 3F2 and 7E6 were obtained from Dr. John Dye (USAMRIID).
Generation of the filovirus phage library
The 90 or 108 nucleotide long oligonucleotides (30 or 36 coding amino acids) were generated by the Bioinformatic analysis pipeline
(see below) and synthesized in high density oligo array pool by a commercial company (CustomArray). Oligo nucleotides were
designed as follows: primer site 1 – EcoRI site – filovirus oligonucleotide – Hind III site – primer site 2. Hind III and EcoRI sites
were used to clone the oligonucleotides in to the T7 phage system (T7select 415-1, EMD Millipore). The primer sites were used to
amplify the original oligonucleotide array pool. The array was amplified with Phusion (Phusion Hot Start Flex DNA Polymerase) using
the following protocol: 1 minute denaturalization at 98C, followed by 33 cycles of 20 s 98C, 15 s 60C, and 1 minute seconds 72C,
and one cycle of final extension for 10 minutes at 72C. After amplification, amplicons were digested with Hind III and EcoRI and
cloned into the T7 systems following the manufacture recommendations. Briefly, after Hind III and EcoRI digestion, the size specific
band (insert) was purified from a 2% agarose gel using the Zymoclean Gel DNA Recovery Kit. Purified insert was quantified by
NanoDrop (Thermo Fisher Scientific). T7select 415-1 RI/Hind III Vector Arms (0.02pmol) and insert (0.06pmol) were ligated using a
T4 DNA ligase (New England Biolabs) for 16 hours at 16C. Five microliters of the T4 ligation reaction was added to 25 ml of T7Select
Packaging Extract and gently mixed by stirring with a pipet tip. The reaction was incubated at room temperature (22C) for 2 h.
Packaging reaction was stopped by adding 270 ml sterile LB medium (Per liter: 10 g Bacto tryptone, 5g Yeast extract, and 10 g
NaCl). A series of dilutions of the packaging reaction was prepared using sterile LBmedium as the diluent. Generally, the appropriate
dilution for recombinant phage was 103 - 106. Sufficient volume of top agarose (Per 100 mL: 1g Bacto tryptone, 0.5g Yeast extract,
0.5g NaCl, and 0.6g agarose) was melted to provide 5 mL for each dilution being plated on LB agar plates 100x15mm (LB Agar per
liter: 10 g Bacto tryptone, 5g Yeast extract, 10 g NaCl, and 15 g agar). A series of 4 mL sterile tubes were prepared by pipetting 250 ml
of BL-21 host cells (overnight culture) into each tube. Starting with the highest dilution, 100 ml of the phage dilution were transferred to
each tube, followed by the addition of 3mL ofmelted top agarose at 45-50C to each tube and the content poured onto a pre-warmed
(37C) LB agar plate. To spread the agarose evenly the plate was immediately gently swirl. The plate was allowed to sit undisturbed
for several minutes until the top agarose hardens, then inverted and incubated at 37C, overnight (12-16 hours). Dilution(s) resulting in
a webbing pattern were used for the phage library amplification. Same protocol as described before is scaled up to a 150 x15mm
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plate (250mL of phage dilution, 625mL of BL-21 host bacteria and 12 mL of top agar). To elute the phages from the plates, each plate
was covered with 10 mL of Phage Extraction Buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 6 mM MgSO4) and placed it on a level
surface at 4C from at least 2 h. Phage were harvested by tipping the plate slightly and pipetting the liquid into a sterile container.
Extract buffer was combined from all the plates in a sterile 50 mL tube or bottle. Chloroform (0.5 ml) was added to each tube and
gently mix. Tubes were centrifuged (Thermo Scientific) at 3,000x g for 5 min to clarify the lysate and the supernatant transferred
to a new sterile tube or bottle. The titer of the amplified phage library was determined by plaque assay. Amplified phage library
can be stored at 4C for several months without a loss of titer. For longer term storage, 0.1 volume of sterile 80% glycerol was added
and the phage library stored at 70C.
Immunoglobulin isotype capture and panning
One hundred microliters of 1 mg/ml of monoclonal antibodies anti-NHP IgM (KPL Catalog number # 071-11-031), IgA (KPL Catalog
number #071-11-011) or IgG (KPL Catalog number #071-11-021) were individually coated into a 96 well bottom immune-plate
(Thermo Scientific. Catalog number: 442404), at 4C for 16 hours. Capture monoclonal antibodies were diluted in a 0.1N NaHCO3
buffer pH = 8.6. Wells were washed three times with PBS and blocked with blocking buffer 10% BSA in 0.1N NaHCO3 (For 50mL:
50mL of 0.1N NaHCO3 + 5g BSA) buffer for 2 hours a room temperature. NHP serum was diluted 1/500 in PBS, 50 mL added to three
different Ig isotype specific coated wells (triplicates), and further incubated at 4C for 16 hours. Before used in panning experiments,
the filovirus phage library was absorbed in wells coated with the Ig isotype specific capture monoclonal antibody and 10% BSA, to
reduce phages unspecifically binding to the capture and blocking reagents. After four washes with 1X TBST buffer (For 1L: 100mL of
10X TBS buffer, 0.5 mL of tween 20 (0.05%), and 1L of dH2O pH = 7.4), 106PFU/50ul of the pre-absorbed phage library was added to
the wells. Panningwas carried out at 4C for 16 hours.Wells were washed 8 timeswith 1X TBST buffer and 100 ml/well of 2M ureawas
added after washing to recover the bound phages. After incubation at 22C for 20 minutes, phages (bound fraction) were collected
and properly stored at 20C until further usage. All samples were processed in triplicates.
Phage library and bound fraction sequencing
The pre-absorbed filovirus library or the recovered phages (bound fraction) were lyzed and cloned oligonucleotide amplified by a PCR
reaction (T7 forward primer: GGAGCTGTCGTA TTC CAG TC / T7 reverse primer: CCCCTC AAG ACCCGT TTAGAGGCCC). Each
primer contained a unique identifier at the 50 end, what allowed the pooling of the triplicates later. A 15 cycles PCR amplification was
performed following the vendor specifications (T7 Clontech). Briefly, the PCR protocol was a 1 minute denaturalization at 98C,
following by cycling of 20 s 98C, 15 s 62C and 45 s 72C. The final extension was performed for 5 minutes at 72C. Each triplicate
was pooled and further cleaned using Zymo-5 column clean up (DNA clean & concentrator-5). DNA from samples was quantified with
Nanodrop and 100ng of DNA was used to perform library preparation. Samples were index coded by performing a 220bp Illumina
library preparation with the Apollo 324 (Wafergen) using the Prep X kit (Wafergen complete IlMN DNA library kit). Libraries were
then enriched using library amplification kit (KAPA) and a post enrichment PCR clean-up was done at the Apollo 324. Individual
libraries were pooled all together at 2nM and sequenced at a MiSeq DNA sequencer instrument using a 600 cycle kit (2x250) with
20% of PhiX. The minimum target sequence depth of approximately 500K reads per library was targeted.
Western-blot analysis
Non-overlapping peptides selected on DPA enriched clusters were synthetized and biotinylated (New England Peptides), with a
peptide linker as a bridge between both molecules. Peptides were diluted to a 1mg/ml final concentration in either water (hydrophilic
residues) or 5% DMSO solution (hydrophobic residues). Biotinylated peptides were conjugated with streptavidin (Invitrogen) in a
2.8/1 molar ratio. The streptavidin-biotin-linker-peptide conjugate was used as antigen in a WES (Protein Simple) system. Assay
conditions were done following the manufacture guidelines (Protein Simple). Biotinylated peptides were mixed with 5X Fluorescent
Standard, DTT, and 1X Sample Buffer (WESReagents) for a final concentration of 0.8 mg of protein, and loaded and run in the capillary
system. Antigenwas detected using the NHP serumdiluted at 1/100, 1/500 or 1/1000 in PBS, and further developed using the isotype
specific antibodies (anti-IgM, KPL Catalog number # 071-11-031; anti-IgA, KPL Catalog number #071-11-011 or anti-IgG, KPL
Catalog number #071-11-021) as secondary reagents. The run was developed using an anti-Goat HRP Antibody and the provided
peroxidase and Luminol-S reagent. Western-blot results were analyzed using the Protein Simple software Compass. Western-blot
was not performed quantitatively, and scored only as ‘‘positive’’ or ‘‘negative.’’
Bioinformatic analysis pipeline
The in-house developed bioinformatic pipeline is divided into modules that perform the following activities: Array Description, Input
Randomization, Removal of Duplicates and Read Mate Correction, Read Cleaning, and Expression Analysis. The DPA analysis
pipeline can be downloaded at https://github.com/kygarcia/DPA_Analysis_Pipeline
1) Array Description
The file input for the system is a gapped amino acid FASTA alignment. These sequences are then divided into overlapping peptides
using awindow and slide specified by the user. For the experiment described in this publication a window of 30 or 36 amino acids and
a slide of 7 amino acids was utilized as indicated. The total peptides are then reduced to the unique set across the sequence space.
Information for the start and stop of the alignment position and the individual sequence position, and the number of sequences that
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contain the exact sequence prior to reduction to the unique set are appended to the peptide name. Oligonucleotides were codon
optimized for E. coli and these are mapped to the original alignment to create a coverage map demonstrating the diversity of oligos
across the sequence space for reporting. This module can be run independently of the analysis of the libraries to create the oligo-
nucleotide array list for synthesis, as well as, turned off during library analysis after the initial run to save time and computing
resources.
2) Input Randomization
Libraries are normalized in vitro during library preparation; however, to reduce anomalous sensitivity effects of sequence output of
varying amounts a read sampling module was implemented. The module randomly selects a specified number of reads from each
library of a project. The number of reads should be limited to the library containing the fewest reads. Available sequence below the
300K threshold described in sequencing can reduce sensitivity. Libraries lower than the threshold can be re-sequenced and added to
the previous project without deleterious effects. Increasing the sequence beyond one million has marginal effect on the sensitivity.
However, sequence to sensitivity is an exponential relationship and the cost in analysis time and reagents is prohibitive.
3) Removal of Duplicates and Read Mate Correction
We utilize the inclusion of a 5 base randomer immediately upstream of the palindromic restriction primer site that flanks the phage
insert to identify erroneously enriched PCR duplicates. A concatamer is created from each read pair and the restriction primer
(T7 forward and reverse primers provided above) a direct match string search is used to identify the restriction primer site on either
flank and locate the random pentamers. An evaluation of the random pentamer from each flank is compared to the identity of the
insert using the first 10 bases of the 50 end of the insert. A direct match is required to identify a duplicate. The truncation of the
comparison, 15 bases from each 50 end is used to reduce the effect on sequencing error on the removal of duplicates. To reduce
the effect of sequencer error we used a 2 3 250 chemistry which completely covers the insert, restriction site, and randomers in
both directions. This allows for alignment of the read 1 sequence to the read 2 sequence. As the fidelity of sequencing drops off
over time in the case of a mismatch between R1 and R2, the higher QC is utilized to correct the sequence. Read 2 is typically of lower
fidelity than read 1 and as such the use of 50 sequence to correct mismatches is extended to 60% of the read length to slightly favor
this increased fidelity. Additionally, the mismatches are counted and a representation of sequencer error as mismatches per base for
the library is presented in the reporting module.
4) Read Cleaning
After read mate correction an exact string match identifying the palindromic primer restriction sites is completed as in ‘Duplicate
removal’ to identify the boundaries of the insert. Themajority of these reads (15%–30%) have been identified to be the loading quality
control (PhiX) included in every run. After identification of the properly formed insert it is excised and short < 30 bp sequences are
removed from the analysis. After short insert removal the remaining inserts are translated into peptides and the length distribution
of the remaining inserts is computed and provided to the reporting tool.
5) Expression Analysis
The peptides of the well-formed inserts are provided as FASTA to a parallelized BLASTX using as reference the peptide sequences
created in the array descriptionmodule. The tabular hit file is parsed and inserts with nomatches are discarded. For each insert query
the top match alignment is binned by full length (Perfect), 67%–99% of reference length (Good), 33%–66% of reference length
(Truncated), and% 32%of reference length (Short). The perfect, good, and truncated lengthmatches are further binned by% identity
to the reference sequence as either 100% (Perfect) or < 100% (Good). This matrix is then subtotaled by reference oligo and totaled
across all oligos to create a hit file. A coverage map displaying the total unique peptides detected, the qualified hits and the short hits
is provided to the reporting tool to demonstrate the quality and diversity of the sequenced phage library. Each library is run as trip-
licate experiments to be used later in statistical analyses. The pipeline is reliant on the three replicates. Replicates failing to sequence
well must be re-sequenced prior to analysis. To control for varying distributions of the peptide oligos synthesized for cloning the input
‘Library’ is also sequenced as a part of every experiment. The Library is also run against a previous known working version of the
Library as a test condition to screen out any run specific anomalies. The bound fractions for the Library, a no Ab negative control
(Negative) and all of the test condition counts are consolidated in a matrix and then compared internally across replicates. The un-
bound fractions are preserved for troubleshooting but have been determined to be under saturating conditions and do not enrich
significantly above the input Library by any condition tested here. The peptide position information is also parsed from the peptide
name and stored in the matrix.
Peptide clustering is achieved by taking all of the alignment positions of all qualified hits andmapping back to the alignments. Each
gap in the alignment consensus is then used as a break point between clusters. These are numbered left to right per alignment and
associated with all of the sequence data of the clusters constituents as the cluster matrix. The cluster matrix is then summarized and
evaluated. For each cluster the cumulative count is calculated by summing the average counts of each peptide and dividing by the
number of peptides in the cluster. These are then compared to the cumulative counts of the corresponding peptides of the Library to
provide cumulative expression values for the cluster. A cluster adjustment is performed by dividing the number of peptides in the
cluster versus all the peptides available in the Library for a similar position. This corrects for differences in highly diverse portions
of the alignment versus well conserved portions of the alignment. The cluster adjustment is then applied to the cumulative counts
and cumulative expression to provide an adjusted counts and expression respectively. All clusters including single sequence clusters
are left in the cluster analysis for the user’s final determination and rank ordered by the adjusted expression score highest to lowest.
The cluster matrix is then provided to the reporting module. Finally, coverage maps displaying the unique test condition hits of the
Cell Reports 24, 1050–1059.e1–e5, July 24, 2018 e4
cluster versus the total unique hits in the library across each gene and the expression of each cluster versus the expression in the
Library across each gene are provided to the reporting tool.
Reporting
The reporting module creates an HTML and EXCEL based output that can be utilized to review results and investigate anomalies. The
home page of the HTML analysis is the summary page. At any point this home page may be reached by clicking the ‘Samples’
hyperlink at the top of the page. Also available there are hyperlinks to the Logs files and methods document containing the user
manual and documentation regarding the analysis process. Each test condition is listed displaying the number of clusters found
and hyperlinks to the cluster analysis, the full peptide analysis, and quality metrics for each replicate. This page acts as a project
summary and a primary navigation tool between test conditions. The full peptide files is an HTML version of the tab delimited file
output pre-clustering. This file is useful for screening the peptides that comprise each cluster but is easier tomanipulate in the EXCEL
version of the report. At the top of the cluster analysis page there are several hyperlinks that reduce the need to scroll and hyperlinks
exist from each section back to the top of the page. They are Enrichment, Alignments, Diversity, Expression and Inserts. The cluster
results presented at the top of the page are the enrichment results sorted from the highest adjusted expression ‘score’ cluster to the
lowest. Each cluster name contains a link to the associated visual representation of the alignment of the peptides within that cluster.
These alignments are sorted from left to right in the order that the oligo appears in the alignment. They can also be accessed by the
Alignments hyperlink at the top of the page or by scrolling. The alignments display the constituents expression values and a visual-
ization of the structure of the cluster in the sequence space. Finally, the alignments contain a consensus sequence and amotif logo to
help the user describe the primary epitopes detected across the cluster. The Diversity section contains all of the coverage maps that
display by gene the detected cluster versus the originating library diversity for visual comparison of the hits in context of their genes.
The Expression section displays the same information but compares total hits versus Library total hits in the context of their genes.
The Inserts section displays the length distribution of the phage inserts sequenced for each replicate and compares to the distribution
of the Library.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
As mentioned above, each library was run as triplicate experiments to be used in statistical analyses. Hits are totaled for each test
condition and values representing the ratio of peptide hits versus total hits are stored for each peptide. The counts are averaged and
stored for each peptide. The peptide hit ratios for each replicate of each test condition are divided by the hit ratio from the
corresponding phage library replicate to provide expression values and stored. Tests for variance between the library and the test
conditions (T-Test) and the test condition and total population of observed values assuming a normal distribution (Chi Square) are
performed. Peptides that fail either the T-Test or the Chi-Square tests with p values > 0.05 are removed from the analysis.
DATA AND SOFTWARE AVAILABILITY
The accession number for the quantitative profiling reported in this paper is BioProject: PRJNA475600 (http://www.ncbi.nlm.nih.gov/
bioproject/475600).
DPA data: SubmissionID: SUB4104551.
DPA analysis pipeline: https://github.com/kygarcia/DPA_Analysis_Pipeline
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